ACRX Falls on Financing, Creating Opportunity Ahead of Phase III Data
Long Ideas - AcelRx (ACRX) will issue and sell up to 11.5M shares of common stock in the coming weeks, just months ahead of a pivotal period for … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
CADX Investor/Analyst Day Highlights Strong Ofirmev Growth Trends
Long Ideas - Cadence Pharmaceuticals (NASDAQ:CADX) hosted its Investor/Analyst Day on Thursday morning, and gave a compelling presentation as to why Ofirmev, its primary value driver, should continue … Continue Reading
Read nowComplete Genomics, BGI, and Illumina: A Corporate Soap Opera
Most Popular - Many investors who choose to invest in the sector choose, for better to worse, to focus only on the clinical and medicinal aspects of these … Continue Reading
Read nowCHTP Still Alive; 306b Trial Supports Northera Efficacy & Safety
Quick Picks - Chelsea Therapeutics (CHTP) released preliminary results for its Phase III clinical study, called 306b, which evaluated the efficacy and safety of Northera, the company’s drug … Continue Reading
Read nowImmunoCellular Shares Near Lows Offers a Speculative Oncology Play
Long Ideas - With its balance sheet shored up after a recent stock offering, shares trading just off of their 52-week lows, and interim Phase IIb data expected … Continue Reading
Read nowQCOR Accelerated Dividend Highlights Acthar Growth
Long Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR) announced a per share cash dividend of $0.20 to shareholders of record on December 14, 2012. The payment is accelerated, as the … Continue Reading
Read nowKalydeco Approval in Canada More Important to Patients than to VRTX
Long Ideas - Finally, some Vertex (NASDAQ:VRTX) news unrelated to Hepatitis C. Health Canada, the Canadian medicinal regulatory body, approved Vertex’s Kalydeco (ivacaftor) on Monday for the treatment … Continue Reading
Read now